Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Brechenmacher

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|August 7, 2015
Mixture-based gatekeeping procedures for multiplicity problems with multiple sequences of hypothesesAlex Dmitrienko, George Kordzakhia, Thomas Brechenmacher
Biometrical Journal. Biometrische Zeitschrift|November 10, 2011
Development of gatekeeping strategies in confirmatory clinical trialsAlex Dmitrienko, Brian A Millen, Thomas Brechenmacher, et al.
Journal of Biopharmaceutical Statistics|April 26, 2011
A mixture gatekeeping procedure based on the Hommel test for clinical trial applicationsThomas Brechenmacher, Jane Xu, Alex Dmitrienko, et al.
The Journal of Pediatrics|February 10, 2016
Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical TrialSergiusz Jóźwiak, Katarzyna Kotulska, Noah Berkowitz, et al.
Journal of Biopharmaceutical Statistics|December 15, 2017
An enhanced mixture method for constructing gatekeeping procedures in clinical trialsGeorge Kordzakhia, Thomas Brechenmacher, Eiji Ishida, et al.
Targeted Oncology|May 20, 2016
Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of EverolimusMarianne Pavel, Nicole Unger, Ivan Borbath, et al.
British Journal of Clinical Pharmacology|November 19, 2015
Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosisKlemens Budde, Bernard A Zonnenberg, Michael Frost, et al.
Clinical Genitourinary Cancer|June 12, 2016
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT TrialsPetri Bono, Stephane Oudard, Istvan Bodrogi, et al.
Breast Cancer Research and Treatment|December 24, 2013
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2J Thaddeus Beck, Gabriel N Hortobagyi, Mario Campone, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 15, 2014
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1J Chris Kingswood, Sergiusz Jozwiak, Elena D Belousova, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|August 7, 2015
Mixture-based gatekeeping procedures for multiplicity problems with multiple sequences of hypothesesAlex Dmitrienko, George Kordzakhia, Thomas Brechenmacher
Biometrical Journal. Biometrische Zeitschrift|November 10, 2011
Development of gatekeeping strategies in confirmatory clinical trialsAlex Dmitrienko, Brian A Millen, Thomas Brechenmacher, et al.
Journal of Biopharmaceutical Statistics|April 26, 2011
A mixture gatekeeping procedure based on the Hommel test for clinical trial applicationsThomas Brechenmacher, Jane Xu, Alex Dmitrienko, et al.
The Journal of Pediatrics|February 10, 2016
Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical TrialSergiusz Jóźwiak, Katarzyna Kotulska, Noah Berkowitz, et al.
Journal of Biopharmaceutical Statistics|December 15, 2017
An enhanced mixture method for constructing gatekeeping procedures in clinical trialsGeorge Kordzakhia, Thomas Brechenmacher, Eiji Ishida, et al.
Targeted Oncology|May 20, 2016
Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of EverolimusMarianne Pavel, Nicole Unger, Ivan Borbath, et al.
British Journal of Clinical Pharmacology|November 19, 2015
Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosisKlemens Budde, Bernard A Zonnenberg, Michael Frost, et al.
Clinical Genitourinary Cancer|June 12, 2016
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT TrialsPetri Bono, Stephane Oudard, Istvan Bodrogi, et al.
Breast Cancer Research and Treatment|December 24, 2013
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2J Thaddeus Beck, Gabriel N Hortobagyi, Mario Campone, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 15, 2014
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1J Chris Kingswood, Sergiusz Jozwiak, Elena D Belousova, et al.
Pageof 1